Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple therapy with oral treprostinil in pulmonary arterial hypertension
NCT02999906Phase 3Withdrawn
- Sponsor
- United Therapeutics Corporation
- Start
- Oct 2017
- Primary completion
- Dec 2021
- Modality
- Orthosteric Ligands
01
Overview
Phase 3, randomised, double-blind trial of treprostinil in pulmonary arterial hypertension (PAH) (2 arms), sponsored by United Therapeutics Corporation. Primary endpoint: Change in 6-Minute Walk Distance at 28 weeks. Planned start Oct 2017; status: withdrawn.
02
Drugs
treprostinil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02999906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02999906.